

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009

Time Report Requested: 13:44:13

First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

F1_M3_Rev1

C Number: C99028
Lock Date: 09/20/2005
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.1.0

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|----------------------------------|---------|-----------|-----------|-----------|
| Disposition Summary | | | | |
| Animals Initially in Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Moribund Sacrifice | 7 | 4 | 2 | 8 |
| Natural Death | 6 | 6 | 6 | 14 |
| Survivors | | | | |
| Moribund Sacrifice | | 1 | | |
| Natural Death | | 1 | | 1 |
| Terminal Sacrifice | 37 | 38 | 42 | 27 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|----------------------------|----------|----------|----------|----------|
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | 1 (2%) |
| Ulcer | | | 1 (2%) | |
| Gallbladder | (50) | (49) | (49) | (50) |
| Inflammation | | | | 1 (2%) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Epithelium, Necrosis | 1 (2%) | | | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Inflammation | | | | 1 (2%) |
| Mineralization | | | | 1 (2%) |
| Epithelium, Diverticulum | | | | 1 (2%) |
| Peyer's Patch, Hyperplasia | 1 (2%) | | 1 (2%) | 1 (2%) |
| Serosa, Inflammation | | | | 1 (2%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis | | 1 (2%) | | |
| Basophilic Focus | 3 (6%) | 1 (2%) | 1 (2%) | 3 (6%) |
| Clear Cell Focus | 26 (52%) | 29 (58%) | 34 (68%) | 16 (32%) |
| Congestion | | | | 1 (2%) |
| Eosinophilic Focus | 26 (52%) | 28 (56%) | 27 (54%) | 27 (54%) |
| Fibrosis | | | 1 (2%) | |
| Hemorrhage | | | | 1 (2%) |
| Infarct | 1 (2%) | 2 (4%) | | 2 (4%) |
| Inflammation | 5 (10%) | 3 (6%) | 5 (10%) | 5 (10%) |
| Mixed Cell Focus | 9 (18%) | 9 (18%) | 9 (18%) | 7 (14%) |
| Regeneration | | | | 1 (2%) |
| Tension Lipidosis | 9 (18%) | 1 (2%) | 3 (6%) | 6 (12%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|--|----------|-----------|-----------|-----------|
| Thrombosis | | | 2 (4%) | 1 (2%) |
| Bile Duct, Cyst | | | | 1 (2%) |
| Centrilobular, Degeneration | | | | 3 (6%) |
| Hepatocyte, Hypertrophy | | 1 (2%) | | 1 (2%) |
| Hepatocyte, Necrosis | 3 (6%) | 2 (4%) | 10 (20%) | 2 (4%) |
| Hepatocyte, Vacuolization Cytoplasmic, Diffuse | 14 (28%) | 11 (22%) | 12 (24%) | 13 (26%) |
| Oval Cell, Hyperplasia | | | 2 (4%) | |
| Serosa, Inflammation | | 1 (2%) | | |
| Mesentery | (5) | (8) | (11) | (1) |
| Inflammation | | | 3 (27%) | 1 (100%) |
| Necrosis | 4 (80%) | 7 (88%) | 7 (64%) | |
| Pancreas | (50) | (50) | (50) | (50) |
| Basophilic Focus | 1 (2%) | | | 1 (2%) |
| Acinus, Atrophy | 1 (2%) | | 1 (2%) | 1 (2%) |
| Acinus, Hyperplasia | 8 (16%) | 4 (8%) | 13 (26%) | 2 (4%) |
| Artery, Inflammation | | 1 (2%) | | |
| Duct, Cyst | | 2 (4%) | 2 (4%) | 2 (4%) |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Edema | | | | 1 (2%) |
| Erosion | | 1 (2%) | | 1 (2%) |
| Inflammation | 1 (2%) | 3 (6%) | | 2 (4%) |
| Ulcer | 1 (2%) | 1 (2%) | 1 (2%) | 7 (14%) |
| Epithelium, Hyperplasia | | 3 (6%) | 1 (2%) | 2 (4%) |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Erosion | | | | 4 (8%) |
| Inflammation | | | 1 (2%) | 1 (2%) |
| Glands, Hyperplasia | | | 1 (2%) | |
| Serosa, Inflammation | | | 1 (2%) | |
| Tongue | (1) | (0) | (0) | (0) |
| Mineralization | 1 (100%) | | | |
| Tooth | (5) | (5) | (4) | (1) |
| Dysplasia | 4 (80%) | 4 (80%) | | 1 (100%) |
| Inflammation | | | 1 (25%) | |
| Peridental Tissue, Fibrosis | | 1 (20%) | 2 (50%) | 1 (100%) |

CARDIOVASCULAR SYSTEM

| | | | | |
|--------------------------|--------|------|--------|--------|
| Blood Vessel | (50) | (50) | (50) | (50) |
| Adventitia, Inflammation | | | 2 (4%) | |
| Heart | (50) | (50) | (50) | (50) |
| Artery, Inflammation | 2 (4%) | | 2 (4%) | |
| Atrium, Thrombosis | | | | 1 (2%) |
| Epicardium, Hyperplasia | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|---|----------|-----------|-----------|-----------|
| Epicardium, Inflammation | 1 (2%) | | 1 (2%) | |
| Myocardium, Cardiomyopathy | 10 (20%) | 12 (24%) | 7 (14%) | 28 (56%) |
| Myocardium, Fibrosis | | 3 (6%) | 3 (6%) | 13 (26%) |
| Myocardium, Infiltration Cellular, Mononuclear Cell | 11 (22%) | 12 (24%) | 8 (16%) | 28 (56%) |
| Myocardium, Mineralization | | 1 (2%) | 2 (4%) | 3 (6%) |
| Myocardium, Necrosis | 3 (6%) | 2 (4%) | | 1 (2%) |
| Myocardium, Vacuolization Cytoplasmic | 10 (20%) | 15 (30%) | 11 (22%) | 29 (58%) |

ENDOCRINE SYSTEM

| | | | | |
|------------------------------|----------|----------|-----------|----------|
| Adrenal Cortex | (49) | (50) | (50) | (50) |
| Degeneration | 1 (2%) | | | |
| Hyperplasia | 13 (27%) | 4 (8%) | 11 (22%) | 2 (4%) |
| Hypertrophy | 24 (49%) | 34 (68%) | 26 (52%) | 22 (44%) |
| Subcapsular, Hyperplasia | 43 (88%) | 44 (88%) | 50 (100%) | 39 (78%) |
| Adrenal Medulla | (49) | (50) | (50) | (50) |
| Hyperplasia | | 2 (4%) | 1 (2%) | |
| Pigmentation, Melanin | | | | 1 (2%) |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Hyperplasia | 32 (64%) | 35 (70%) | 39 (78%) | 21 (42%) |
| Parathyroid Gland | (47) | (33) | (45) | (46) |
| Cyst | 1 (2%) | | | 2 (4%) |
| Pituitary Gland | (50) | (49) | (49) | (49) |
| Pars Distalis, Cyst | 6 (12%) | 1 (2%) | 3 (6%) | 3 (6%) |
| Pars Distalis, Hyperplasia | 20 (40%) | 5 (10%) | 17 (35%) | 5 (10%) |
| Pars Intermedia, Cyst | 1 (2%) | | | |
| Thyroid Gland | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | | | |
| Follicle, Cyst | | | 2 (4%) | |
| Follicular Cell, Hyperplasia | | | | 2 (4%) |

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

| | | | | |
|-----------------|--------|--------|--------|--------|
| Epididymis | (50) | (50) | (50) | (50) |
| Atrophy | 1 (2%) | | | |
| Granuloma Sperm | | 1 (2%) | 2 (4%) | |
| Inflammation | 4 (8%) | | 1 (2%) | 4 (8%) |
| Preputial Gland | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|-----------------------------------|----------|-----------|-----------|-----------|
| Fibrosis | | | 1 (2%) | |
| Inflammation | 2 (4%) | 3 (6%) | 2 (4%) | 1 (2%) |
| Duct, Ectasia | 3 (6%) | 4 (8%) | | 1 (2%) |
| Prostate | (50) | (50) | (50) | (50) |
| Atrophy | 1 (2%) | | | |
| Inflammation | 1 (2%) | | 2 (4%) | 3 (6%) |
| Epithelium, Hyperplasia | 16 (32%) | 4 (8%) | 3 (6%) | 6 (12%) |
| Seminal Vesicle | (50) | (50) | (50) | (50) |
| Atrophy | 1 (2%) | | | |
| Dilatation | | | 1 (2%) | |
| Testes | (50) | (50) | (50) | (50) |
| Mineralization | 1 (2%) | 1 (2%) | | |
| Germinal Epithelium, Degeneration | 11 (22%) | 7 (14%) | 6 (12%) | 9 (18%) |
| Interstitial Cell, Hyperplasia | 1 (2%) | | | |

HEMATOPOIETIC SYSTEM

| | | | | |
|----------------------------------|--------|--------|--------|--------|
| Bone Marrow | (50) | (50) | (50) | (50) |
| Angiectasis | | 1 (2%) | | |
| Atrophy | 1 (2%) | | | |
| Hemorrhage | 1 (2%) | | | 2 (4%) |
| Myelofibrosis | | | 1 (2%) | |
| Lymph Node | (2) | (1) | (2) | (1) |
| Lymph Node, Mandibular | (50) | (50) | (50) | (50) |
| Hyperplasia, Plasma Cell | 1 (2%) | 1 (2%) | | 2 (4%) |
| Lymph Node, Mesenteric | (50) | (50) | (50) | (49) |
| Hemorrhage | 1 (2%) | | | 2 (4%) |
| Hyperplasia, Lymphoid | | | 1 (2%) | |
| Hyperplasia, Plasma Cell | | 1 (2%) | | |
| Spleen | (50) | (50) | (50) | (50) |
| Atrophy | 3 (6%) | 1 (2%) | 1 (2%) | 1 (2%) |
| Hematopoietic Cell Proliferation | | | 1 (2%) | 1 (2%) |
| Thymus | (49) | (49) | (47) | (49) |
| Inflammation | | | 1 (2%) | |

INTEGUMENTARY SYSTEM

| | | | | |
|--|----------|--------|--------|----------|
| Mammary Gland | (1) | (0) | (0) | (0) |
| Duct, Dilatation | 1 (100%) | | | |
| Skin | (50) | (50) | (50) | (50) |
| Ulcer | 1 (2%) | 1 (2%) | | 1 (2%) |
| Site Of Application - Dermis, Fibrosis | 6 (12%) | 1 (2%) | 2 (4%) | 25 (50%) |
| Site Of Application - Dermis, Inflammation | 3 (6%) | 1 (2%) | 3 (6%) | 13 (26%) |
| Site Of Application - Epidermis, Hyperplasia | 8 (16%) | 1 (2%) | 4 (8%) | 28 (56%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|--|----------|-----------|-----------|------------------|
| Site Of Application - Epidermis, Ulcer Subcutaneous Tissue, Edema | 3 (6%) | 1 (2%) | 1 (2%) | 4 (8%) 1 (2%) |
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (50) | (50) | (50) | (50) |
| Cartilage, Femur Joint, Hyperplasia | 1 (2%) | | | |
| Femur, Joint, Inflammation | 1 (2%) | | | |
| Skeletal Muscle | (0) | (0) | (0) | (1) |
| NERVOUS SYSTEM | | | | |
| Brain | (50) | (50) | (50) | (50) |
| Ventricle, Inflammation | 1 (2%) | | | |
| RESPIRATORY SYSTEM | | | | |
| Lung | (50) | (50) | (50) | (50) |
| Inflammation | 3 (6%) | 3 (6%) | | |
| Thrombosis | | 1 (2%) | 1 (2%) | |
| Alveolar Epithelium, Hyperplasia | 2 (4%) | 1 (2%) | 3 (6%) | 2 (4%) |
| Alveolus, Infiltration Cellular, Histocyte | 3 (6%) | 1 (2%) | | |
| Mediastinum, Inflammation | | 1 (2%) | | |
| Perivascular, Cyst | | 1 (2%) | | |
| Serosa, Hyperplasia | | 1 (2%) | | |
| Nose | (50) | (50) | (50) | (50) |
| Inflammation | 8 (16%) | 3 (6%) | 2 (4%) | 3 (6%) |
| Respiratory Epithelium, Hyperplasia | 1 (2%) | | 1 (2%) | |
| SPECIAL SENSES SYSTEM | | | | |
| Eye | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | 1 (2%) | | | |
| Cornea, Hyperplasia | | | | 1 (2%) |
| Cornea, Inflammation | 3 (6%) | | | |
| Retrolbulbar, Inflammation | 1 (2%) | | | |
| Harderian Gland | (50) | (50) | (50) | (49) |
| Cyst | 1 (2%) | | | |
| Hemorrhage | | | | 1 (2%) |
| Epithelium, Hyperplasia | | | 2 (4%) | |
| Zymbal's Gland | (1) | (0) | (0) | (1) |
| Cyst | 1 (100%) | | | 1 (100%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
bis(2-Chloroethoxy)methane
CAS Number: 111-91-1

Date Report Requested: 08/26/2009
Time Report Requested: 13:44:13
First Dose M/F: 10/03/02 / 10/02/02
Lab: BAT

| B6C3F1 MICE MALE | 0 MG/KG | 150 MG/KG | 300 MG/KG | 600 MG/KG |
|------------------|----------|-----------|-----------|-----------|
| Inflammation | 1 (100%) | | | |

URINARY SYSTEM

| | | | | |
|---|----------|----------|----------|----------|
| Kidney | (50) | (50) | (50) | (50) |
| Cyst | 7 (14%) | 8 (16%) | 11 (22%) | 11 (22%) |
| Hydronephrosis | 5 (10%) | 1 (2%) | 3 (6%) | 1 (2%) |
| Infarct | | 1 (2%) | 1 (2%) | |
| Infiltration Cellular, Mononuclear Cell | | 3 (6%) | | |
| Inflammation | 4 (8%) | 2 (4%) | 4 (8%) | 1 (2%) |
| Mineralization | 22 (44%) | 26 (52%) | 21 (42%) | 25 (50%) |
| Nephropathy | 45 (90%) | 42 (84%) | 44 (88%) | 37 (74%) |
| Artery, Inflammation | 2 (4%) | | 2 (4%) | |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Mineralization | 1 (2%) | | | |

*** END OF MALE ***

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|----------------------------------|---------|-----------|-----------|-----------|
| Disposition Summary | | | | |
| Animals Initially in Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Moribund Sacrifice | 11 | 5 | 7 | 11 |
| Natural Death | 8 | 7 | 6 | 2 |
| Survivors | | | | |
| Natural Death | | | | 1 |
| Terminal Sacrifice | 31 | 38 | 37 | 36 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|----------------------------------|----------|----------|----------|----------|
| Esophagus | (50) | (50) | (50) | (50) |
| Inflammation | | | 1 (2%) | |
| Gallbladder | (50) | (50) | (50) | (50) |
| Fibrosis | 1 (2%) | | | |
| Epithelium, Cyst | | | | 1 (2%) |
| Epithelium, Hyperplasia | 1 (2%) | | | |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | | 1 (2%) | | |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | | 1 (2%) | | |
| Epithelium, Diverticulum | 1 (2%) | | | |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Arteriole, Inflammation | | 1 (2%) | | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Inflammation | | 1 (2%) | 1 (2%) | |
| Ulcer | | 1 (2%) | | |
| Epithelium, Diverticulum | | 1 (2%) | | |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Epithelium, Hyperplasia | | | | 1 (2%) |
| Peyer's Patch, Diverticulum | 1 (2%) | | | |
| Peyer's Patch, Hyperplasia | | 2 (4%) | | 1 (2%) |
| Liver | (50) | (50) | (50) | (50) |
| Angiectasis | | | 2 (4%) | 2 (4%) |
| Basophilic Focus | 1 (2%) | 2 (4%) | 2 (4%) | |
| Clear Cell Focus | 1 (2%) | 3 (6%) | | 5 (10%) |
| Eosinophilic Focus | 12 (24%) | 9 (18%) | 11 (22%) | 12 (24%) |
| Hematopoietic Cell Proliferation | | | | 1 (2%) |
| Infarct | 1 (2%) | | | |
| Inflammation | 8 (16%) | 10 (20%) | 15 (30%) | 10 (20%) |
| Mitotic Alteration | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|--|----------|-----------|-----------|-----------|
| Mixed Cell Focus | 1 (2%) | 1 (2%) | | 1 (2%) |
| Pigmentation, Hemosiderin | | | 1 (2%) | 1 (2%) |
| Regeneration | | 1 (2%) | 1 (2%) | |
| Tension Lipidosis | 7 (14%) | 6 (12%) | 5 (10%) | 8 (16%) |
| Bile Duct, Cyst | | | 1 (2%) | 1 (2%) |
| Hepatocyte, Hypertrophy | | | | 1 (2%) |
| Hepatocyte, Mineralization | 1 (2%) | | | |
| Hepatocyte, Necrosis | 2 (4%) | 4 (8%) | 2 (4%) | 3 (6%) |
| Hepatocyte, Vacuolization Cytoplasmic | | 1 (2%) | | |
| Hepatocyte, Vacuolization Cytoplasmic, Diffuse | 3 (6%) | 1 (2%) | 5 (10%) | 3 (6%) |
| Serosa, Fibrosis | 1 (2%) | | | 1 (2%) |
| Serosa, Inflammation | 2 (4%) | 1 (2%) | | |
| Mesentery | (16) | (13) | (11) | (10) |
| Inflammation | | | 2 (18%) | 2 (20%) |
| Necrosis | 14 (88%) | 13 (100%) | 8 (73%) | 7 (70%) |
| Pancreas | (50) | (50) | (50) | (50) |
| Basophilic Focus | | | | 2 (4%) |
| Inflammation | 1 (2%) | | | |
| Acinus, Atrophy | | 2 (4%) | | |
| Acinus, Hyperplasia | 6 (12%) | 3 (6%) | 7 (14%) | 9 (18%) |
| Arteriole, Inflammation | | | | 1 (2%) |
| Duct, Cyst | 1 (2%) | 2 (4%) | | |
| Duct, Inflammation | | | 1 (2%) | |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Inflammation | 2 (4%) | | | |
| Ulcer | 1 (2%) | | | |
| Epithelium, Hyperplasia | 5 (10%) | 5 (10%) | 13 (26%) | 5 (10%) |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Mineralization | | 2 (4%) | | |
| Epithelium, Cyst | | | | 1 (2%) |
| Epithelium, Hyperplasia | 2 (4%) | 1 (2%) | 1 (2%) | |
| Glands, Cyst | | | 1 (2%) | 3 (6%) |
| Glands, Hyperplasia | | 2 (4%) | | |
| Tooth | (0) | (0) | (2) | (3) |
| Dysplasia | | | | 2 (67%) |
| Inflammation | | | 1 (50%) | |
| Gingiva, Hyperplasia | | | | 1 (33%) |
| Peridontal Tissue, Fibrosis | | | | 2 (67%) |
| Peridontal Tissue, Inflammation | | | | 1 (33%) |
| CARDIOVASCULAR SYSTEM | | | | |
| Blood Vessel | (50) | (50) | (50) | (50) |

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|---|-----------|-----------|-----------|-----------|
| Aorta, Inflammation | | 1 (2%) | | |
| Heart | (50) | (50) | (50) | (50) |
| Artery, Inflammation | 1 (2%) | 3 (6%) | 2 (4%) | 1 (2%) |
| Atrium, Thrombosis | | | 1 (2%) | 1 (2%) |
| Epicardium, Inflammation | | | | 1 (2%) |
| Myocardium, Cardiomyopathy | 10 (20%) | 7 (14%) | 10 (20%) | 17 (34%) |
| Myocardium, Fibrosis | 1 (2%) | 1 (2%) | | 2 (4%) |
| Myocardium, Infiltration Cellular, Mononuclear Cell | 9 (18%) | 7 (14%) | 10 (20%) | 17 (34%) |
| Myocardium, Mineralization | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) |
| Myocardium, Necrosis | 1 (2%) | | | |
| Myocardium, Vacuolization Cytoplasmic | 14 (28%) | 4 (8%) | 6 (12%) | 13 (26%) |
| Valve, Thrombosis | 1 (2%) | | | |
| ENDOCRINE SYSTEM | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) |
| Angiectasis | | | | 1 (2%) |
| Atrophy | 1 (2%) | | | |
| Hyperplasia | 11 (22%) | 11 (22%) | 7 (14%) | 11 (22%) |
| Hypertrophy | 38 (76%) | 46 (92%) | 42 (84%) | 40 (80%) |
| Subcapsular, Hyperplasia | 50 (100%) | 50 (100%) | 50 (100%) | 48 (96%) |
| Adrenal Medulla | (50) | (50) | (50) | (50) |
| Hyperplasia | 6 (12%) | 2 (4%) | 7 (14%) | 2 (4%) |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Hyperplasia | 23 (46%) | 23 (46%) | 31 (62%) | 21 (42%) |
| Pituitary Gland | (49) | (50) | (50) | (50) |
| Pars Distalis, Angiectasis | 1 (2%) | 2 (4%) | | |
| Pars Distalis, Cyst | 2 (4%) | 1 (2%) | 1 (2%) | 3 (6%) |
| Pars Distalis, Hyperplasia | 24 (49%) | 27 (54%) | 24 (48%) | 27 (54%) |
| Pars Intermedia, Hyperplasia | | | 1 (2%) | |
| Thyroid Gland | (50) | (50) | (50) | (50) |
| Inflammation | 1 (2%) | 1 (2%) | | |
| C-cell, Hyperplasia | | | 1 (2%) | |
| Follicle, Cyst | 1 (2%) | | 1 (2%) | 1 (2%) |
| Follicular Cell, Hyperplasia | | 2 (4%) | 1 (2%) | 1 (2%) |
| GENERAL BODY SYSTEM | | | | |
| None | | | | |
| GENITAL SYSTEM | | | | |

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|------------------------------------|----------|-----------|-----------|-----------|
| Clitoral Gland | (50) | (50) | (49) | (50) |
| Inflammation | | 1 (2%) | 1 (2%) | |
| Ovary | (50) | (50) | (50) | (50) |
| Angiectasis | | 1 (2%) | | |
| Cyst | 13 (26%) | 7 (14%) | 7 (14%) | 15 (30%) |
| Hemorrhage | 2 (4%) | 1 (2%) | | 3 (6%) |
| Mineralization | | 1 (2%) | | |
| Pigmentation, Hemosiderin | 1 (2%) | | | |
| Thrombosis | | | | 1 (2%) |
| Interstitial Cell, Hyperplasia | | | | 1 (2%) |
| Periovarian Tissue, Inflammation | 2 (4%) | | | |
| Uterus | (50) | (50) | (50) | (50) |
| Hemorrhage | | | | 1 (2%) |
| Endometrium, Hyperplasia, Cystic | 49 (98%) | 47 (94%) | 48 (96%) | 50 (100%) |
| Myometrium, Angiectasis | 1 (2%) | | | |
| Myometrium, Cyst | | | | 1 (2%) |
| Vagina | (0) | (0) | (1) | (0) |
| HEMATOPOIETIC SYSTEM | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) |
| Angiectasis | | | 1 (2%) | |
| Myelofibrosis | 8 (16%) | 3 (6%) | 8 (16%) | 11 (22%) |
| Lymph Node | (8) | (9) | (3) | (5) |
| Iliac, Degeneration, Cystic | 1 (13%) | | | |
| Iliac, Hemorrhage | 1 (13%) | | | |
| Lumbar, Hyperplasia, Lymphoid | 1 (13%) | | | |
| Pancreatic, Hyperplasia, Lymphoid | | 1 (11%) | | |
| Renal, Hyperplasia, Lymphoid | 1 (13%) | | | |
| Lymph Node, Mandibular | (50) | (50) | (50) | (49) |
| Infiltration Cellular, Plasma Cell | | | | 1 (2%) |
| Lymph Node, Mesenteric | (50) | (50) | (49) | (50) |
| Infiltration Cellular, Plasma Cell | | | 1 (2%) | |
| Necrosis | | | 1 (2%) | |
| Arteriole, Inflammation | | 1 (2%) | | |
| Spleen | (50) | (50) | (50) | (50) |
| Hematopoietic Cell Proliferation | 2 (4%) | 1 (2%) | 3 (6%) | 1 (2%) |
| Hyperplasia, Lymphoid | 1 (2%) | 4 (8%) | | 1 (2%) |
| Infiltration Cellular, Plasma Cell | | | 2 (4%) | |
| Capsule, Hyperplasia | 1 (2%) | | | |
| Thymus | (50) | (50) | (50) | (50) |
| Atrophy | | | 1 (2%) | |
| Hyperplasia, Lymphoid | | | 1 (2%) | 3 (6%) |

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|--|----------|-----------|-----------|-----------|
| INTEGUMENTARY SYSTEM | | | | |
| Mammary Gland | (48) | (50) | (50) | (50) |
| Skin | (50) | (50) | (50) | (50) |
| Site Of Application - Dermis, Fibrosis | 4 (8%) | 1 (2%) | | 2 (4%) |
| Site Of Application - Dermis, Inflammation | 4 (8%) | 2 (4%) | 1 (2%) | 1 (2%) |
| Site Of Application - Epidermis, Hyperplasia | 3 (6%) | 1 (2%) | 3 (6%) | 3 (6%) |
| Site Of Application - Epidermis, Ulcer | 1 (2%) | | 1 (2%) | |
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (50) | (50) | (50) | (50) |
| NERVOUS SYSTEM | | | | |
| Brain | (50) | (50) | (50) | (50) |
| Spinal Cord | (2) | (0) | (1) | (0) |
| Demyelination | 1 (50%) | | 1 (100%) | |
| RESPIRATORY SYSTEM | | | | |
| Lung | (50) | (50) | (50) | (50) |
| Hemorrhage | 1 (2%) | | | |
| Infiltration Cellular | | 1 (2%) | | |
| Inflammation | 1 (2%) | 1 (2%) | | 1 (2%) |
| Alveolar Epithelium, Hyperplasia | 5 (10%) | 1 (2%) | 4 (8%) | 4 (8%) |
| Alveolus, Infiltration Cellular, Histiocyte | 1 (2%) | 1 (2%) | | 2 (4%) |
| Arteriole, Inflammation | | 1 (2%) | | |
| Serosa, Hyperplasia | | | | 1 (2%) |
| Nose | (50) | (50) | (50) | (50) |
| Inflammation | 13 (26%) | 8 (16%) | 7 (14%) | 6 (12%) |
| Polyp, Inflammatory | | | 1 (2%) | |
| Glands, Olfactory Epithelium, Dilatation | 1 (2%) | | 1 (2%) | |
| Glands, Respiratory Epithelium, Dilatation | | 1 (2%) | 1 (2%) | |
| Respiratory Epithelium, Hyperplasia | | | | 2 (4%) |
| Septum, Cyst | | | 1 (2%) | |
| Pleura | (0) | (0) | (1) | (0) |
| SPECIAL SENSES SYSTEM | | | | |
| Eye | (50) | (50) | (50) | (50) |
| Cornea, Inflammation | | 2 (4%) | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 bis(2-Chloroethoxy)methane
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009
 Time Report Requested: 13:44:13
 First Dose M/F: 10/03/02 / 10/02/02
 Lab: BAT

| B6C3F1 MICE FEMALE | 0 MG/KG | 100 MG/KG | 200 MG/KG | 400 MG/KG |
|---|----------|-----------|-----------|-----------|
| Retina, Dysplasia | | | 1 (2%) | 1 (2%) |
| Harderian Gland | (50) | (50) | (50) | (50) |
| Epithelium, Hyperplasia | 12 (24%) | 7 (14%) | 6 (12%) | 4 (8%) |
| URINARY SYSTEM | | | | |
| Kidney | (50) | (50) | (50) | (50) |
| Infarct | 1 (2%) | 1 (2%) | 3 (6%) | 3 (6%) |
| Infiltration Cellular, Mononuclear Cell | 4 (8%) | 1 (2%) | 1 (2%) | 1 (2%) |
| Inflammation | 4 (8%) | | | |
| Mineralization | 9 (18%) | 8 (16%) | 11 (22%) | 9 (18%) |
| Nephropathy | 37 (74%) | 37 (74%) | 42 (84%) | 38 (76%) |
| Capsule, Fibrosis | 1 (2%) | | | |
| Renal Tubule, Dilatation | | 1 (2%) | | |
| Renal Tubule, Pigmentation | | 1 (2%) | | |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Amyloid Deposition | | | | 1 (2%) |
| Hyperplasia, Lymphoid | | | | 1 (2%) |
| Inflammation | | | | 1 (2%) |
| Inflammation, Chronic | 1 (2%) | | | |
| Arteriole, Inflammation | | | 1 (2%) | |
| Arteriole, Muscularis, Degeneration | | 1 (2%) | | |

*** END OF REPORT ***